Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system
Abstract
Cognitive impairments during psychotic episodes are assumed to be caused not only by one single putative classical neurotransmitter dysfunction but also by an impaired equilibrium of the interaction between different neurobiological generators of cognitive processes. Herein, the perceptual abnormalities induced by psychotogenic agents play a major role as tools for the understanding of model psychoses. The recently discovered cannabinoid receptor system with its endogenous ligand anandamide can be regarded as an extremely relevant regulator system, a dysfunctionality of which may explain at least one subtype of endogenous psychoses. Neuropsychological results (three-dimensional inversion illusion) in delta 9-tetrahydrocannabinol-intoxicated normal volunteers exhibit strong similarities with data acquired from patients suffering from productive schizophrenic psychoses, regarding disturbances in internal regulation of perceptual processes. The relevance of this finding to a general cognitive dysfunction concept of schizophrenic psychosis is discussed.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Induction of pro-psychotic states in non-clinical populations via acute cannabinoids, chronic intoxication, or sleep deprivation experimentally reduces sensitivity to visual illusions.
“other studies have suggested that the induction of “pro-psychotic” states in non-clinical populations, via, for example, acute cannabinoids (Emrich et al., 1997; Leweke et al., 1999; Koethe et al., 2006), chronic intoxication (Semple et al., 2003) or sleep deprivation (Sternemann et al., 1997), enable to experimentally reduce sensitivity to VIs.”
From What visual illusions teach us about schizophrenia (2014) · cites this paper as Emrich et al., 1997
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633 · see citing works
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · see citing works
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,389 · see citing works
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · see citing works
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · see citing works
Molecular pathology of schizophrenia: more than one disease process?
Crow, T. J. (1980) · BMJ · doi:10.1136/bmj.280.6207.66 · Cited by 1,863 · see citing works
Dopamine receptor pharmacology
Seeman, P. M., & Tol, H. H. M. V. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90323-9 · Cited by 969 · see citing works
BONE-MARROW TRANSPLANTATION IN A PATIENT WITH THE WISKOTT-ALDRICH SYNDROME
Bach, F. H., Albertini, R., Joo, P., Anderson, J., & Bortin, M. M. (1968) · The Lancet · doi:10.1016/s0140-6736(68)92672-x · Cited by 867 · see citing works
Hollister, L. E. (1987) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(87)90030-4 · Cited by 500 · see citing works
Significance and meaning of neurological signs in schizophrenia
Heinrichs, D. W., & Buchanan, R. W. (1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.1.11 · Cited by 433 · see citing works
Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor
Hanus, L. O., Gopher, A., Almog, S., & Mechoulam, R. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00072a026 · Cited by 334 · see citing works
Facilitation of brain stimulation reward byΔ 9-tetrahydrocannabinol
Gardner, E. L., Paredes, W. M., Smith, D. M., Donner, A., Milling, C., Cohen, D., & Morrison, D. (1988) · Psychopharmacology · doi:10.1007/bf02431546 · Cited by 204 · see citing works
Marijuana's interaction with brain reward systems: Update 1991
Gardner, E. L., & Lowinson, J. H. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90365-9 · Cited by 197 · see citing works
Psychotic Reactions Following Cannabis Use in East Indians
Chopra, G. S. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760070014002 · Cited by 191 · see citing works
CANNABIS-ASSOCIATED PSYCHOSIS WITH HYPOMANIC FEATURES
Rottanburg, D. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91270-3 · Cited by 179 · see citing works
Schizophrenia in users and nonusers of cannabis
Andréasson, S., Allebeck, P., & Rydberg, U. S. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb10296.x · Cited by 157 · see citing works
Influence of cannabis abuse on schizophrenic psychopathology
Peralta, V., & Cuesta, M. J. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb01456.x · Cited by 155 · see citing works
Psychiatric Symptoms in Cannabis Users
Thomas, H. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.163.2.141 · Cited by 145 · see citing works
The Clinical Correlates of Neurological Soft Signs in Chronic Schizophrenia
King, D. J., Wilson, A. C., Cooper, S. J., & Waddington, J. L. (1991) · The British Journal of Psychiatry · doi:10.1192/bjp.158.6.770 · Cited by 123 · see citing works
Cannabis Psychosis and Paranoid Schizophrenia
Thacore, V. R. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770030081012 · Cited by 116 · see citing works
Marihuana Use and Psychiatric Illness
Halikas, J. A. (1972) · Archives of General Psychiatry · doi:10.1001/archpsyc.1972.01750260016003 · Cited by 77 · see citing works
A Comment on the "Amotivational Syndrome" in Marijuana Smokers
Kupfer, D. J., DETRE, T. P., Koral, J., & Fajans, P. (1973) · American Journal of Psychiatry · doi:10.1176/ajp.130.12.1319 · Cited by 69 · see citing works
Visual 3D illusion: A systems-theoretical approach to psychosis
Schmeider, U., Leweke, F. M., Sternemann, U., Emrich, H. M., & Weber, M. M. (1996) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02190277 · Cited by 57 · see citing works
Self-citationA Three-Component-System Hypothesis of Psychosis
Emrich, H. M. (1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000295962 · Cited by 55 · see citing works
Self-citationA Selective Review of Biological Markers in Schizophrenia
Szymanski, S., Kane, J. M., & Lieberman, J. A. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.1.99 · Cited by 48 · see citing works
Δ9-Tetrahydrocannabinol facilitates striatal dopaminergic transmission
Sakurai‐Yamashita, Y., Kataoka, Y., Fujiwara, M., Mine, K., & Ueki, S. (1989) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(89)90521-2 · Cited by 45 · see citing works
Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen
Mailleux, P., & Vanderhaeghen, J. (1994) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(94)90110-4 · Cited by 26 · see citing works
SPENCER, D. J. (1970) · British Journal of Addiction to Alcohol & Other Drugs · doi:10.1111/j.1360-0443.1970.tb03956.x · Cited by 26 · see citing works
Zur Psychopathologie und Differentialdiagnose sogenannter Cannabispsychosen
Täschner, K.-L. (1983) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-2007-1002229 · Cited by 21 · see citing works
Regional brain catecholamines and metabolites following THC, PCP and MK-801
Mb, B., & Norton, J. B. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90111-2 · Cited by 20 · see citing works
Genetics of Major Psychiatric Disorders
Ciaranello, R. D., & Ciaranello, A. L. (1991) · Annual Review of Medicine · doi:10.1146/annurev.me.42.020191.001055 · Cited by 19 · see citing works
Wright, I. C., & Woodruff, P. W. R. (1995) · CNS Drugs · doi:10.2165/00023210-199503020-00005 · Cited by 17 · see citing works
Crow, T. J. (1994) · Current Opinion in Psychiatry · doi:10.1097/00001504-199401000-00011 · Cited by 9 · see citing works
Flagged first, then by citations
2 of the 35 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · see citing works
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024 · see citing works
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · see citing works
Marsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937 · see citing works
Iversen, L. L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 735 · see citing works
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 576 · see citing works
Giuffrida, A., Leweke, F. M., Gerth, C. W., Schreiber, D., Koethe, D., Faulhaber, J., Klosterkötter, J., & Piomelli, D. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300558 · Cited by 481 · see citing works
Self-citationElevated endogenous cannabinoids in schizophrenia
Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999) · Neuroreport · doi:10.1097/00001756-199906030-00008 · Cited by 431 · see citing works
Self-citationSchneider, M., & Koch, M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300225 · Cited by 425 · see citing works
Cannabis as a risk factor for psychosis: Systematic review
Semple, D. M., McIntosh, A. M., & Lawrie, S. M. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105049040 · Cited by 420 · see citing works
van der Stelt, M., & Marzo, V. D. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.101 · Cited by 286 · see citing works
Cannabinoids in Clinical Practice
Williamson, E. M., & Evans, F. J. (2000) · Drugs · doi:10.2165/00003495-200060060-00005 · Cited by 283 · see citing works
Tests of causal linkages between cannabis use and psychotic symptoms
Fergusson, D. M., Horwood, L. J., & Ridder, E. M. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01001.x · Cited by 268 · see citing works
Zavitsanou, K., Garrick, T. M., & Huang, X. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.11.005 · Cited by 264 · see citing works
Endocannabinoid signalling in the blood of patients with schizophrenia.
Marchi, N. D., PETROCELLIS, L. D., Orlando, P., Daniele, F., Fezza, F., & Marzo, V. D. (2003) · Lipids in Health and Disease · doi:10.1186/1476-511x-2-5 · Cited by 266 · see citing works
Therapeutic Potential of Cannabinoids in CNS Disease
Croxford, J. L. (2003) · CNS Drugs · doi:10.2165/00023210-200317030-00004 · Cited by 240 · see citing works
Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models
Malone, D. T., Hill, M. N., & Rubino, T. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00721.x · Cited by 237 · see citing works
CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia
Ujike, H., Takaki, M., Nakata, K., Tanaka, Y., Takeda, T., Kodama, M., Fujiwara, Y., Sakai, A., & Kuroda, S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001029 · Cited by 228 · see citing works
Cannabinoids in health and disease
Kogan, N. M., & Mechoulam, R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/nkogan · Cited by 227 · see citing works
Cannabis and psychiatric disorders: it is not only addiction
Leweke, F. M., & Koethe, D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00106.x · Cited by 213 · see citing works
Self-citationIversen, L. L. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328240.001.0001 · Cited by 230 · see citing works
Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice
Moreira, F. A., & Guimarães, F. S. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.02.040 · Cited by 206 · see citing works
Dima, D., Roiser, J. P., Dietrich, D. E., Bonnemann, C., Lanfermann, H., Emrich, H. M., & Dillo, W. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.03.033 · Cited by 192 · see citing works
Self-citationAssies, J., Lieverse, R., Vreken, P., WANDERS, R. J. A., Dingemans, P. M. A. J., & Linszen, D. H. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00986-0 · Cited by 188 · see citing works
Endocannabinoids in the central nervous system-an overview
Fride, E. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2001.0360 · Cited by 186 · see citing works
What visual illusions teach us about schizophrenia
Notredame, C.-E., Pins, D., Deneve, S., & Jardri, R. (2014) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2014.00063 · Cited by 177 · see citing works
Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes
Bersani, G., Orlandi, V., Kotzalidis, G. D., & Pancheri, P. (2002) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-002-0366-5 · Cited by 176 · see citing works
Lipids in Psychiatric Disorders and Preventive Medicine
Schneider, M., Levant, B., Reichel, M., Gulbins, E., Kornhuber, J., & Müller, C. P. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.002 · Cited by 175 · see citing works
Different Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man
Leweke, F. M., Schneider, U., Radwan, M., Schmidt, E., & Emrich, H. M. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00201-x · Cited by 150 · see citing works
Self-citationVisual Perception Disturbances in Schizophrenia: A Unified Model
Silverstein, S. M. (2016) · Nebraska Symposium on Motivation/The Nebraska symposium on motivation · doi:10.1007/978-3-319-30596-7_4 · Cited by 144 · see citing works
Centonze, D., Battista, N., Rossi, S., Mercuri, N. B., Finazzi‐Agrò, A., Bernardi, G., Calabresi, P., & Maccarrone, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300458 · Cited by 143 · see citing works
From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis
Mechoulam, R., & Ben‐Shabat, S. (1999) · Natural Product Reports · doi:10.1039/a703973e · Cited by 139 · see citing works
Gorriti, M. Á., de Fonseca, F. R., Navarro, M., & Palomo, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00851-6 · Cited by 135 · see citing works
Molecular biology of cannabinoid receptors
Lutz, B. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2001.0342 · Cited by 135 · see citing works
Role of the endocannabinoid system in depression and suicide
Vinod, K. Y., & Hungund, B. L. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.08.006 · Cited by 132 · see citing works
Candidate genes for cannabis use disorders: findings, challenges and directions.
Agrawal, A., & Lynskey, M. T. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02504.x · Cited by 128 · see citing works
Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia
Müller‐Vahl, K., & Emrich, H. M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.7.1037 · Cited by 126 · see citing works
Self-citationHallak, J. E. C., Machado‐de‐Sousa, J. P., Crippa, J. A. S., Sanches, R. F., Trzesniak, C. M. F., Chaves, C., Bernardo, S. A., Regalo, S. C. H., & Zuardi, A. W. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000100011 · Cited by 125 · see citing works
Impaired top-down processes in schizophrenia: a DCM study of ERPs
Dima, D., Dietrich, D. E., Dillo, W., & Emrich, H. M. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.12.086 · Cited by 122 · see citing works
Self-citationPálóczi, J., Varga, Z. V., Hasko, G., & Pacher, P. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7144 · Cited by 121 · see citing works
A review of abnormalities in the perception of visual illusions in schizophrenia
Griffiths-King, D. J., Hodgekins, J., Chouinard, P. A., Chouinard, V., & Sperandio, I. (2016) · Psychonomic Bulletin & Review · doi:10.3758/s13423-016-1168-5 · Cited by 112 · see citing works
Müller‐Vahl, K., Prevedel, H., Theloe, K., KOLBE, H., Emrich, H. M., & Schneider, U. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300047 · Cited by 111 · see citing works
Self-citationKöfalvi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3 · Cited by 110 · see citing works
Reduced binocular depth inversion in schizophrenic patients
Schneider, U., Borsutzky, M., Seifert, J., Leweke, F. M., Huber, T. J., Rollnik, J. D., & Emrich, H. M. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00172-9 · Cited by 108 · see citing works
Self-citationThe cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats
Schneider, M., & Koch, M. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200202000-00003 · Cited by 108 · see citing works
Seillier, A., Advani, T., Cassano, T., Hensler, J. G., & Giuffrida, A. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570999023x · Cited by 105 · see citing works
Two cases of "cannabis acute psychosis" following the administration of oral cannabis
Favrat, B., Ménétrey, A., Augsburger, M. P., Rothuizen, L. E., Appenzeller, M., Buclin, T., Pin, M. A., Mangin, P. J., & Giroud, C. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-17 · Cited by 100 · see citing works
Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
Rohleder, C., Müller, J. K., Lange, B., & Leweke, F. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00422 · Cited by 94 · see citing works
Self-citationUjike, H., & Morita, Y. (2004) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fmj04003x4 · Cited by 95 · see citing works
Biological hypotheses, risk factors, and biomarkers of schizophrenia
Fišar, Z. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110626 · Cited by 97 · see citing works
Koethe, D., Gerth, C. W., Neatby, M. A., Haensel, A., Thies, M., Schneider, U., Emrich, H. M., Klosterkötter, J., Schultze-Lutter, F., & Leweke, F. M. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.023 · Cited by 93 · see citing works
Self-citationTherapeutic Potential of Cannabinoids in Psychosis
Leweke, F. M., Mueller, J. K., Lange, B., & Rohleder, C. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.018 · Cited by 92 · see citing works
Self-citationSchmack, K., Schnack, A., Priller, J., & Sterzer, P. (2015) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2015.03.005 · Cited by 88 · see citing works
Cannabis‐induced psychosis: a cross‐sectional comparison with acute schizophrenia
Núñez, L. A., & Manuel Gurpegui, A. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.1o079.x · Cited by 91 · see citing works
Rodríguez-Muñoz, M., Sánchez‐Blázquez, P., Merlos, M., & Garzón-Niño, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10095 · Cited by 87 · see citing works
Roser, P., Juckel, G., Rentzsch, J., Nadulski, T., Gallinat, J., & Stadelmann, A. M. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.04.008 · Cited by 88 · see citing works
Bersani, G., Orlandi, V., Gherardelli, S., & Pancheri, P. (2002) · Psychopathology · doi:10.1159/000067064 · Cited by 87 · see citing works
Skosnik, P. D., & Yao, J. K. (2003) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.08.008 · Cited by 86 · see citing works
Xie, S., Furjanic, M. A., Ferrara, J., McAndrew, N. R., Ardino, E. L., Ngondara, A., Bernstein, Y., Thomas, K. J., Kim, E., Walker, J. M., et al. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00817.x · Cited by 82 · see citing works
Alonso, R., Voutsinos‐Porche, B., Fournier, M., Labie, C., Steinberg, R., Souilhac, J., Fur, G. L., & Soubrié, P. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00675-7 · Cited by 80 · see citing works
D’Addario, C., Micale, V., Bartolomeo, M. D., Štark, T., Pucci, M., Šulcová, A., Palazzo, C., Babinská, Z., Cremaschi, L., Drago, F., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.01.022 · Cited by 79 · see citing works
Wilkinson, S. (2014) · Consciousness and Cognition · doi:10.1016/j.concog.2014.09.002 · Cited by 77 · see citing works
The effect of Δ9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats
Malone, D. T., & TAYLOR, D. A. H. B. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.07.009 · Cited by 77 · see citing works
The role of Cannabinoids in neurodegenerative diseases
Glass, M. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00162-2 · Cited by 76 · see citing works
Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum
Guimaraes, V. H. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.01.015 · Cited by 75 · see citing works
Nagai, H., Egashira, N., Sano, K., Ogata, A., Mizuki, A., Mishima, K., Iwasaki, K., Shoyama, Y., Nishimura, R., & Fujiwara, M. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.05.018 · Cited by 75 · see citing works
Reduced binocular depth inversion in regular cannabis users
Semple, D. M., Ramsden, F., & McIntosh, A. M. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(03)00140-0 · Cited by 74 · see citing works
Skosnik, P. D., Krishnan, G. P., Aydt, E. E., Kuhlenshmidt, H. A., & O’Donnell, B. F. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.10.1798 · Cited by 72 · see citing works
Cannabis and psychosis: an update on course and biological plausible mechanisms
LINSZEN, D. H., & van Amelsvoort, T. (2007) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32803577fb · Cited by 71 · see citing works
Psychosis and synthetic cannabinoids
Deng, H., Verrico, C. D., Kosten, T. R., & Nielsen, D. A. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.012 · Cited by 68 · see citing works
Juckel, G., Roser, P., Nadulski, T., Stadelmann, A. M., & Gallinat, J. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.08.015 · Cited by 63 · see citing works
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists
Roser, P., Vollenweider, F. X., & Kawohl, W. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970801908047 · Cited by 63 · see citing works
The endocannabinoid system: a physiological perspective on its role in psychomotor control
Giuffrida, A., & Piomelli, D. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00193-6 · Cited by 63 · see citing works
Synthetic Δ-9-Tetrahydrocannabinol (Dronabinol) Can Improve the Symptoms of Schizophrenia
SCHWARCZ, G., Karajgi, B. M., & McCarthy, R. H. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a6bc3b · Cited by 62 · see citing works
Leweke, F. M., Gerth, C. W., & tter, J. K. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00005 · Cited by 60 · see citing works
Self-citationCurrent pharmacological models of social withdrawal in rats
Gururajan, A., TAYLOR, D. A. H. B., & Malone, D. T. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833fa7df · Cited by 59 · see citing works
Potvin, S., Kouassi, É., Lipp, O., Bouchard, R.-H., Roy, M., Demers, M., Gendron, A., Astarita, G., Piomelli, D., & Stip, É. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107083816 · Cited by 59 · see citing works
Robinson, S. A., Loiacono, R. E., Christopoulos, A., Sexton, P. M., & Malone, D. T. (2010) · Brain Research · doi:10.1016/j.brainres.2010.04.031 · Cited by 57 · see citing works
Phytocannabinoids and Endocannabinoids
Fišar, Z. (2009) · Current Drug Abuse Reviews · doi:10.2174/1874473710902010051 · Cited by 56 · see citing works
González, S. R., Romero, J., de Miguel, R., Lastres‐Becker, I., Villanúa, M. A., Makriyannis, A., Ramos, J. A., & Fernández‐Ruíz, J. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00251-9 · Cited by 56 · see citing works
Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists
Hill, M. N., Froese, L. M., Morrish, A. C., Sun, J. C., & Floresco, S. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0421-4 · Cited by 55 · see citing works
Roser, P., Gallinat, J., Weinberg, G., Juckel, G., Gorynia, I., & Stadelmann, A. M. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0868-5 · Cited by 54 · see citing works
Berding, G., Müller-Vahl, K., Schneider, U., Gielow, P., Fitschen, J., Stuhrmann, M., Harke, H., Buchert, R., Donnerstag, F., Hofmann, M., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.005 · Cited by 54 · see citing works
Self-citationEmerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era
Marino, M. J., Knutsen, L. J. S., & Williams, M. R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701094q · Cited by 52 · see citing works
Is the perception of illusions abnormal in schizophrenia?
Grzeczkowski, L., Roinishvili, M., Chkonia, E. D., Brand, A., Mast, F. W., Herzog, M. H., & Shaqiri, A. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.10.063 · Cited by 51 · see citing works
Modulation of cannabinoid agonist binding by 5‐HT in the rat cerebellum
Devlin, M. G., & Christopoulos, A. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2002.00797.x · Cited by 51 · see citing works
Voicu, V. A., Brehar, F.-M., Toader, C., Covache-Busuioc, R.-A., Corlatescu, A.-D., Bordeianu, A., Costin, H. P., Bratu, B.-G., Glavan, L.-A., & Ciurea, A. V. (2023) · Biomolecules · doi:10.3390/biom13091388 · Cited by 49 · see citing works
Drugs of abuse and increased risk of psychosis development
Gururajan, A., Manning, E. E., Klug, M., & van den Buuse, M. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412455232 · Cited by 50 · see citing works
Coulston, C. M., Perdices, M., & Tennant, C. C. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701634952 · Cited by 48 · see citing works
Sensory gating impairments in heavy cannabis users are associated with altered neural oscillations.
Edwards, C. R., Skosnik, P. D., Steinmetz, A. B., O’Donnell, B. F., & Hetrick, W. P. (2009) · Behavioral Neuroscience · doi:10.1037/a0016328 · Cited by 47 · see citing works
Alterations of consciousness: an empirical analysis for social scientists
(2003) · Choice Reviews Online · doi:10.5860/choice.41-1233 · Cited by 47 · see citing works
Leweke, F. M., Mueller, J. K., Lange, B., Fritze, S., Topor, C. E., Koethe, D., & Rohleder, C. (2018) · CNS Drugs · doi:10.1007/s40263-018-0539-z · Cited by 47 · see citing works
Self-citationGanesh, S., Cortes-Briones, J., Ranganathan, M., Radhakrishnan, R., Skosnik, P. D., & D’Souza, D. C. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa031 · Cited by 44 · see citing works
Affect processing and positive syndrome schizotypy in cannabis users
Skosnik, P. D., Park, S., Dobbs, L., & Gardner, W. L. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2007.02.010 · Cited by 41 · see citing works
Dissanayake, D. W. N., Zachariou, M., Marsden, C. A., & Mason, R. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.039 · Cited by 41 · see citing works
Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets
Ľupták, M., Michaličková, D., Fišar, Z., Kitzlerová, E., & Hroudová, J. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i7.277 · Cited by 39 · see citing works
Cannabinoid Receptors and Their Relationships with Neuropsychiatric Disorders
Gambi, F., Berardis, D. D., Sepede, G., Quartesan, R., Calcagni, E., Salerno, R. M., Conti, C. M., & Ferro, F. M. (2005) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200501800103 · Cited by 41 · see citing works
Finkelstein, J. M., Heemels, M.-T., Shadan, S., & Weiss, U. K. (2014) · Nature · doi:10.1038/510047a · Cited by 40 · see citing works
Pharmacological and molecular targets in the search for novel antipsychotics
Scatton, B., & Sanger, D. J. (2000) · Behavioural Pharmacology · doi:10.1097/00008877-200006000-00008 · Cited by 39 · see citing works
CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice
Khella, R., Short, J. L., & Malone, D. T. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3481-x · Cited by 38 · see citing works
- Authors
- Emrich, H. M., Leweke, F. M., & Schneider, U.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Emrich, Hinderk M
- Venue
- Pharmacology Biochemistry and Behavior
- Publisher
- Elsevier BV
- Published
- 1997-04
- Volume
- 56
- Issue
- 4
- Pages
- 803-807
- ISSN
- 0091-3057 (ISSN-L)
- OpenAlex
- W1986173065
- Cited by
- 226
- References
- 35
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 6 · 2020: 2 · 2019: 5 · 2018: 16 · 2017: 7 · 2016: 8 · 2015: 5 · 2014: 8 · 2013: 3 · 2012: 8
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacology Biochemistry and Behavior (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- schizophrenia, endocannabinoid system, anandamide, cognitive impairment, perceptual disorders, cannabinoid receptors, psychosis
- MeSH terms
- Adult, Cannabinoids, Depth Perception, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Receptors, Drug, Schizophrenia, Schizophrenic Psychology, Vision, Binocular, Receptors, Cannabinoid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review